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Abstract 
The delivery of safe and effective radical cure for Plasmodium vivax is one of the greatest challenges for achieving 
malaria elimination from the Asia–Pacific by 2030. During the annual meeting of the Asia Pacific Malaria Elimina‑
tion Network Vivax Working Group in October 2016, a round table discussion was held to discuss the programmatic 
issues hindering the widespread use of primaquine (PQ) radical cure. Participants included 73 representatives from 16 
partner countries and 33 institutional partners and other research institutes. In this meeting report, the key discussion 
points are presented and grouped into five themes: (i) current barriers for glucose‑6‑phosphate deficiency (G6PD) 
testing prior to PQ radical cure, (ii) necessary properties of G6PD tests for wide scale deployment, (iii) the promo‑
tion of G6PD testing, (iv) improving adherence to PQ regimens and (v) the challenges for future tafenoquine (TQ) 
roll out. Robust point of care (PoC) G6PD tests are needed, which are suitable and cost‑effective for clinical settings 
with limited infrastructure. An affordable and competitive test price is needed, accompanied by sustainable funding 
for the product with appropriate training of healthcare staff, and robust quality control and assurance processes. In 
the absence of quantitative PoC G6PD tests, G6PD status can be gauged with qualitative diagnostics, however none 
of the available tests is currently sensitive enough to guide TQ treatment. TQ introduction will require overcoming 
additional challenges including the management of severely and intermediately G6PD deficient individuals. Robust 
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Malaria Journal
*Correspondence:  kamala.ley‑thriemer@menzies.edu.au 
1 Global and Tropical Health Division, Menzies School of Health Research 
and Charles Darwin University, Darwin, Australia
Full list of author information is available at the end of the article
Page 2 of 9Thriemer et al. Malar J  (2017) 16:141 
Background
In November 2014, the governments of the Asia–Pacific 
nations reconfirmed their commitment to the regional 
elimination of malaria by 2030. Although major gains in 
malaria control have been made over the last two dec-
ades, these successes have been far less apparent for Plas-
modium vivax than for Plasmodium falciparum. Once 
regarded as a relatively benign disease, vivax malaria is 
now acknowledged as an important public health con-
cern leading to life-threatening complications, miscar-
riage, chronic infection and increased mortality [1–3]. P. 
vivax poses specific difficulties to elimination, mainly due 
to its ability to relapse weeks to months after the initial 
infection [4]. The propensity of P. vivax to form dormant 
liver stages (hypnozoites) leading to recurrent infections, 
requires specific strategies to achieve its elimination, 
including the provision of radical cure to treat both the 
blood and dormant liver stages of the parasite.
The only widely available drug to treat hypnozoites is 
primaquine (PQ), a drug which can cause haemolysis 
when administered to patients with a glucose-6-phos-
phate-dehydrogenase (G6PD) enzyme deficiency [5]. 
G6PD deficiency (G6PDd) is the most common enzy-
mopathy worldwide, with more than 185 clinically rel-
evant G6PD variants reported [6], conferring varying 
degrees of phenotypic deficiency. The gene encoding the 
G6PD enzyme is located on the X-chromosome, hence 
males can be hemizygous normal (wildtype) or deficient, 
whereas women can be homozygous-, heterozygous-
deficient or normal for the G6PD variants. Heterozygous 
females harbour two distinct populations of red blood 
cells (RBCs), a G6PD normal and a G6PDd fraction. In 
heterozygous females the distribution of G6PDd and 
G6PD normal RBCs is determined at random through a 
process called lyonization [7]. Accordingly, heterozygous 
females with the same G6PD alleles can manifest differ-
ent degrees of deficiency.
As a result of these factors, the risk of haemolysis var-
ies with the dose of PQ administered, the level of G6PD 
enzyme activity and the genetic variant of G6PDd. The 
World Health Organization’s (WHO) malaria treat-
ment guidelines recommend that PQ is administered 
over 14 days to reduce the risk of severe haemolysis [8], 
but such a prolonged treatment course poses significant 
issues regarding adherence that limits the regimens’ 
effectiveness. Tafenoquine (TQ), another 8-aminoquino-
line compound which is currently at the end of it’s Phase 
3 clinical programme has a significantly longer half-life 
than PQ, allowing it to be administered as a single dose 
regimen. Like PQ, TQ can cause severe haemolysis in 
G6PDd individuals, and it will therefore be crucial to 
determine the G6PD status prior to prescribing the 
drug to mitigate the risk of sustained haemolysis (Justin 
Green, pers. comm.).
Currently only 7 malaria-endemic countries in the 
Asia–Pacific region and Sri Lanka, which is malaria 
free,  recommend G6PD testing prior to PQ treatment 
(Table  1) [9]. However few countries have introduced 
G6PD testing into routine practice due to considerable 
barriers for its public health deployment [10].
The Asia Pacific Malaria Elimination Network 
and the Vivax Working Group
The Asia Pacific Malaria Elimination Network (APMEN) 
in conjunction with the Asia Pacific Malaria Alliance 
(APLMA) is a regional network of National Malaria Con-
trol Programmes (NMCPs) and research partners work-
ing together to overcome the challenges for the regional 
elimination of malaria. At the initial APMEN meeting 
in 2009, P. vivax was identified as a key challenge for the 
regional malaria elimination. The Vivax Working Group 
(VxWG) was established to identify key knowledge gaps 
impeding the control of vivax malaria [11]. The VxWG 
provides a forum for its members to prioritise research 
activities that will provide the necessary evidence for 
policy makers to change policy and impact on health 
outcomes. The group comprises representatives from 18 
NMCPs, a wide range of research partner institutes, the 
WHO, as well as a variety of consortia and industry rep-
resentatives. The working group follows a cyclical process 
as described in detail previously [11]. Annual workshops, 
meetings and consultations are a critical part of the 
groups work to build consensus, set common agendas 
and foster partnerships.
Round table discussion “Incorporation of G6PD 
testing for P. vivax case management, how and 
when to use it”
The annual VxWG meeting was held in October 2016 
in Bali Indonesia with 73 representatives from 16 part-
ner countries and 33 institutional partners and other 
research institutes. During this meeting a round table 
discussion was held to discuss the incorporation of 
G6PD testing for P. vivax case management and how 
strategies are needed to ensure that effective treatment practices can be deployed widely, and these should ensure 
that the caveats are outweighed by  the benefits of radical cure for both the patients and the community. Widespread 
access to quality controlled G6PD testing will be critical.
Keywords: Vivax malaria, P. vivax, Radical cure, Primaquine, APMEN, Tafenoquine
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and when to use it. The specific questions posed to the 
forum are listed in Table  2. The key discussion points 
arising from this session are grouped into five overarch-
ing issues: (i) current barriers for G6PD testing for PQ 
radical cure, (ii) necessary properties of G6PD tests for 
wide scale deployment, (iii) the promotion of G6PD 
testing, (iv) improving the adherence to a complete PQ 
treatment course and (v) challenges for future TQ roll 
out.
Topic 1: current barriers for G6PD testing for PQ 
radical cure
The WHO malarial treatment guidelines were revised 
recently, including a statement that good practice 
requires that the G6PD status of patients should be ascer-
tained prior to administration of PQ [8]. Implementing 
routine testing for G6PDd is challenging in the absence 
of a robust, affordable point of care (PoC) test and is not 
yet universally accepted. Hence the WHO guidelines also 
state that if testing is unavailable, an individual risk–ben-
efit assessment should guide the decision on whether or 
not to prescribe PQ (Table 3) [8].
National policies vary considerably from country to 
country, with only 7 of the 20 malaria-endemic coun-
tries in the Asia–Pacific region and Sri Lanka, which is 
malaria free, currently recommending testing for G6PDd 
prior to prescribing PQ (Table 1) [9]. In some countries it 
was acknowledged that the actual clinical practise differs 
from the guidelines. Identifying and addressing the barri-
ers for the introduction of G6PD testing will help to pro-
mote the safe delivery of PQ. Furthermore, since G6PD 
testing will likely be a prerequisite for TQ prescription, 
which may demand far more stringent criteria, ensur-
ing the widespread implementation of G6PD testing will 
greatly facilitate the roll out of this new treatment once it 
becomes available.
Many participants questioned the need for routine 
G6PD testing prior to PQ radical cure, perceiving the risk 
of drug induced severe haemolysis to be low, and citing 
extensive experience in treating patients with PQ with 
very few reports of severe adverse events. This percep-
tion was echoed in a more formal study undertaken in 
four of the APMEN partner countries [10]. Many partici-
pants proposed that in certain populations and locations 
Table 1 Countries in the APMEN region and their recommendation in regards to vivax treatment and G6PD testing prior 
to PQ administration, based on WHO’s World Malaria Report, 2016 [9]
a WHO report states “no” in the respective section, but PQ included in current guidelines
b Unclear from WHO report
c data from WHO world malaria report 2015 [57], since Sri Lanka is not anymore included in the 2016 report




G6PD testing  
recommended in guidelines
Year policy on G6PD 
testing adopted
Bangladesh CQ + PQ (14 days at 0.25 mg/kg) 2008 No
Bhutan CQ + PQ (14 days at 0.25 mg/kg) Unknown No
Cambodia DHA‑PPQ + PQ (14 days at 0.25 mg/kg) 2013 Yes 2012
China CQ + PQ (8 days at 0.75 mg/kg) 1970 No
Democratic People’s 
Republic of Korea
CQ + PQ (14 days at 0.25 mg/kg) 2000 No
India CQ + PQ (14 days at 0.25 mg/kg) 1982 No
Indonesia DHA‑PPQ + PQ (14 days at 0.25 mg/kg) 2004 No
Lao People’s Democratic 
Republic
CQ + PQ (14 days at 0.25 mg/kg) Unknowna Yes 2010
Malaysia CQ + PQ (14 days at 0.5 mg/kg) 1993 Yes 1993
Myanmar CQ + PQ (14 days at 0.25 mg/kg) 1951 No
Nepal CQ + PQ (14 days at 0.25 mg/kg) 2009 Yes Unknown
Papua New Guinea AL + PQ (14 days at 0.25 mg/kg) 2009 No
Philippines CQ + PQ (14 days) 2002 or  2007b Yes 2009
Republic of Korea CQ + PQ (14 days at 0.25 mg/kg) 2001 No
Solomon Islands AL + PQ (14 days at 0.25 mg/kg) 2009 Yes 2009
Sri  Lankac CQ + PQ (14 days at 0.25 mg/kg) Unknown Yes Unknown
Thailand CQ + PQ (14 days at 0.25 mg/kg) 1965 Yes 2015
Timor‑Leste CQ + PQ (14 days at 0.5 mg/kg) 2006 No
Vanuatu AL + PQ (14 days at 0.25 mg/kg) 2009 Yes 2009
Vietnam CQ + PQ (14 days at 0.25 mg/kg) 1960 No
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it would be safe to prescribe PQ without prior G6PD 
testing.
A counter argument to this approach was raised that, 
since there was a lack of formal pharmacovigilance sys-
tems the occurrence of severe adverse events would be 
rarely recognised or recorded. A comprehensive review 
of reported PQ induced toxicity documented an overall 
risk of mortality as 1 in 621,428 [12]. However there are 
several reports of severe PQ toxicity and in some cases 
these were fatal [13, 14]. Most of these reports were not 
accompanied by corresponding denominators for the 
number of patients exposed and hence there is a degree 
of uncertainty about the absolute risk of haemolysis and 
how this varies with different G6PD variants. The Medi-
terranean and Mediterranean-like G6PDd variants are of 
particular concern because of severe PQ induced haemo-
lytic anaemia that is not self-limiting [15].
The perceived need for G6PD testing therefore depends 
on a balance of the population-level risk of drug induced 
haemolysis and the benefits of achieving radical cure. 
The healthcare priority for managing a patient with acute 
malaria is the reduction in asexual parasitaemia and 
achieving symptom resolution. In this context the pre-
scriber and/or patient may not perceive the immediate 
expediency of preventing future relapse which occur in 
only a proportion of patients and often do not manifest 
clinically for weeks or even months [16]. Each recurrent 
bout of parasitaemia is associated with parasite induced 
haemolysis and haemopoietic suppression resulting in 
a cumulative risk of severe anaemia [17]. The morbidity 
and mortality associated with recurrent infections will 
vary between geographical populations, access to health-
care, and the prevailing relapse patterns [18]. Hence the 
risk–benefit assessment varies, depending on the clini-
cal setting and the specific application of PQ, such as the 
treatment of symptomatic patients, terminal prophylaxis 
in healthy but exposed individuals and even mass drug 
administration [19, 20]. The risk–benefit also depends 
on the progress of malaria elimination in the respective 
setting. In countries with low endemicity close to malaria 
elimination the risk of reinfection is low and reappear-
ance of parasites is mainly caused by relapses rendering 
radical cure highly beneficial. The ability of the health 
system to ensure adherence to treatment is an addi-
tional variable that should be included in the risk–benefit 
assessment, since incomplete treatment only provides the 
risks, but not the benefits of radical cure.
The logistics of delivering diagnostics in many malaria 
endemic areas are substantial. At the round table discus-
sions participants raised concerns regarding the cost-
effectiveness of G6PD testing in areas with low risk of 
PQ induced haemolysis. In countries with limited public 
health resources this issue becomes crucial for imple-
mentation routine G6PD testing and policy makers must 
be convinced that G6PD testing adds value and is good 
use of available funding. Economic studies to address this 
are currently underway in a number of Asian countries 
[21]. Preliminary modelling data from the Thai-Myanmar 
border suggests that there is a potential reduction in total 
healthcare costs when using G6PD testing prior to PQ 
compared to PQ treatment without testing. These savings 
result from averting drug induced haemolytic episodes 
and the cumulative impact of P. vivax relapses [22].
Participants from NMCPs highlighted the financial 
challenges, and the barriers of ensuring appropriate 
training and quality control practices. Furthermore the 
logistical challenges of maintaining a supply chain and 
suitable storage facilities are paramount in order to use 
tests within their expiry dates. This is especially impor-
tant for low endemic settings where only a few vivax 
patients are seen, but stocks would need to be kept up to 
date.
Wide-scale introduction of G6PD testing for vivax 
patients will require the availability of easy to use, reli-
able PoC tests with robust performance indicators [6]. 
Several participants discussed the difficulties of intro-
ducing malaria Rapid Diagnostic Tests (RDTs) includ-
ing the practice of adhering to guidelines when the RDT 
result was negative [23–25] and the variable utilization in 
some settings [26–30]. Although the lessons learnt from 
Table 2 Questions posed to participants for the round table discussions
1 Should G6PD testing always be done prior to prescribing primaquine? (What does the current WHO recommendation mean for your program?)
2 What are the key barriers for introducing routine G6PD testing? (e.g. barriers at decision maker level, at provider level)
3 How can we promote G6PD testing prior to primaquine or tafenoquine? (e.g. what evidence is needed to make a case for testing, how can it be 
funded, what should it cost, what support is needed?)
4 What will be the challenges rolling out tafenoquine?
5 How would you provide G6PD testing when tafenoquine is rolled out? (E.g. at what level? Who will test? How will the results be recorded? Testing 
before every episode? Are there areas with high P.v. burden where you believe G6PD testing would not be feasible? If so, what alternatives 
could be considered?)
6 How can we encourage primaquine usage for radical cure?
7 How can we improve treatment adherence? (e.g. are there specific issues with adherence in hard to reach populations and how to solve them?)
8 What kinds of tests do we need for routine G6PD testing? (e.g. test format, operational characteristics, training involved, cost per test etc.)
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the introduction of malaria RDTs are relevant to G6PD 
testing, the former are required for diagnosing an acute 
infection, whereas the latter are required for safety and 
prevention of future infections [31], and thus the experi-
ence and challenges are often different.
Topic 2: necessary properties of G6PD test for wide 
scale deployment
Most endemic countries where G6PD testing is carried 
out routinely rely on the fluorescent spot test (FST) as 
the primary diagnostic tool. In some cases the FST is 
backed up by spectrophotometer based quality control 
systems (e.g. Malaysia). Whilst the FST is widely used, 
it has a number of limitations including difficulties in its 
interpretation, the need for basic laboratory infrastruc-
ture and an extended time to result of at least 30–45 min, 
rendering the test unsuitable for PoC testing [6]. The FST 
has a cut-off enzyme activity at approximately 30% of the 
adjusted male median [32]. Whilst this threshold is cur-
rently widely believed to be suitable to guide PQ treat-
ment, it is not sufficient to guide TQ treatment and the 
manufacturers recommendations will likely require an 
individual’s enzyme activity to be greater than 70% [5, 
33].
The FST provides a qualitative test result and is unable 
to diagnose heterozygous females who can have G6PD 
activity between 30 and 70%. In heterozygous females the 
fraction of RBCs with G6PD normal activity produces a 
G6PD normal result, however following PQ administra-
tion, the fraction of G6PDd RBCs will be subject to drug 
induced haemolysis, which can result in a substantial 
drop in haemoglobin. In settings where the FST is already 
used as a routine diagnostic, there is no immediate need 
for a change of practice to other tests as long as medical 
staff is aware of the test’s shortcomings in heterozygous 
females.
Two test formats have been introduced to the market 
within recent years. One of these is a lateral flow assay 
based on a colorimetric reaction that provides a quali-
tative G6PD result within less than 15  min. The most 
widely used lateral flow assay is the CareStart G6PD 
RDT (Accessbio, USA) with operational characteristics 
suitable for application in the field [6]. The test has been 
evaluated thoroughly and in most cases found to perform 
comparably to the FST [34–38]. It has a similar cut-off 
activity to the FST and hence it is not suitable for guiding 
treatment with TQ [6] however its superior operational 
characteristics and price [6, 37] make it a useful alterna-
tive to the FST prior to PQ treatment.
The second test format is a quantitative biosensor 
(Accessbio, USA). The Biosensor measures electrochemi-
cal properties of a blood sample and provides a quantita-
tive G6PD activity reading that requires normalizing by 
a haemoglobin measurement or RBC count. While the 
performance of the current biosensor is not yet sufficient 
to replace the FST, the format addresses two important 
shortcomings of all other currently available PoC tests 
[39]. The machine can provide a quantitative reading 
making it adaptable to different test-and-treat scenarios 
in which drug therapy may be based on different enzyme 
cut-offs. Unlike the lateral flow format the biosensor 
can identify heterozygous females with G6PD activities 
between 30 and 70% of the adjusted male median [32]. 
Some participants had concerns that the quantitative 
outcome was too complex for basic field applications. 
However it may be possible to convert the biosensor 
Table 3 Relevant section from WHO guidelines on G6PD testing for PQ based radical cure [8]
Statement Section
The G6PD status of patients should be used to guide administration of PQ for preventing 
relapse. Good practise statement
Executive summary—page 11
Treatment of uncomplicated malaria caused by P. 
vivax, P. ovale, P. malariae or P. knowlesi—page 60
When G6PD status is unknown and G6PD testing is not available, a decision to prescribe PQ 
must be based on an assessment of the risks and benefits of adding PQ. Good practise state‑
ment
Executive summary—page 11
Treatment of uncomplicated malaria caused by P. 
vivax, P. ovale, P. malariae or P. knowlesi—page 60
Given the benefits of preventing relapse and in the light of changing epidemiology worldwide 
and more aggressive targets for malaria control and elimination, the group now recommends 
that PQ be used in all settings
Treatment of uncomplicated malaria caused by P. 
vivax, P. ovale, P. malariae or P. knowlesi—page 68
In the absence of quantitative testing, all females should be considered as potentially having 
intermediate G6PD activity and given the 14‑day regimen of PQ, with counselling on how to 
recognize symptoms and signs of haemolytic anaemia
Treatment of uncomplicated malaria caused by P. 
vivax, P. ovale, P. malariae or P. knowlesi—page 69
If G6PD testing is not available, a decision to prescribe or withhold PQ should be based on the 
balance of the probability and benefits of preventing relapse against the risks of PQ induced 
haemolytic anaemia. This depends on the population prevalence of G6PD deficiency, the 
severity of the prevalent genotypes and on the capacity of health services to identify and 
manage PQ induced haemolytic reactions
Treatment of uncomplicated malaria caused by P. 
vivax, P. ovale, P. malariae or P. knowlesi—page 69
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outcome into a qualitative reading according to prede-
fined absolute cut-off activities.
Next generation biosensors are being developed which 
will have improved performance and if successful these 
will facilitate greatly the transition from PQ to TQ based 
radical cure. This advance in diagnostics is likely to come 
at greater financial costs since the biosensor and corre-
sponding supplies are significantly more expensive (500 
USD/machine, 2.50 USD/test) than the CareStart G6PD 
RDT (1.50 USD/test) and the FST (<$1/test) [6].
Topic 3: promoting the roll out of G6PD testing
Participants discussed the criteria that need to be met 
before NMCPs can endorse G6PD testing to support PQ 
based radical cure. These were: (i) a clear risk–benefit 
and cost-effectiveness assessment of G6PD testing, (ii) 
the availability of a robust tests that is reliable in field set-
tings with limited infrastructure, (iii) a competitive and 
affordable price for the test and (iv) secured and sustain-
able funding for the test, for training of health care staff 
and associated quality control processes. The first three 
points were discussed in topics 1 and 2 above.
Appropriate training of health care workers and labo-
ratory personnel is needed at all relevant levels of the 
health system, with an emphasis on the management of 
G6PDd patients and appropriate monitoring on adher-
ence to guidelines. Successful introduction and scale up 
of testing will require a system of quality assurance and 
monitoring mechanisms that should start at the moment 
of sample collection. This would also need to encompass 
the correct recording and reporting of results and subse-
quent adherence to respective treatment algorithms.
Country partners mentioned significant logistical chal-
lenges regarding the introduction of routine G6PD test-
ing and emphasised the lack of evidence on how routine 
G6PD testing could be achieved nationally. Several par-
ticipants called for pilot projects where efforts could be 
made to identify and address logistical bottlenecks and 
provide reassurance of feasibility. In a pilot project in 
Thailand CareStart™ G6PD RDTs were deployed in 62 
selected malaria clinics in 16 provinces (personal com-
munication Suravadee Kitchakam). The main challenges 
encountered were around the procurement process, the 
training of staff, the interpretation of test results and 
following treatment algorithms. Lessons learned from 
this kind of pilot studies will be help NMCPs to focus 
resources to achieve widespread deployment.
Topic 4: improving the adherence to a full course 
of primaquine treatment
Adherence to the currently recommended 14  day PQ 
regimen is challenging. Previous studies have shown that 
adherence to a full course of 14 days is often low [40–43] 
and, whilst this may be mitigated by a shorter treatment 
course [21], even unsupervised 7 days regimens may be 
compromised by poor adherence [44]. On the other hand, 
the experience with tuberculosis (TB) and HIV suggests 
that extended treatment courses are feasible. Directly 
observed treatment (DOT) is used to improve adher-
ence to TB treatment and has been shown to improve 
outcomes for malaria as well [41, 42]. Many partici-
pants commented on the importance of context specific 
solutions, rather than a “one size fits all” approach. For 
example, in a very low endemic setting such as Malaysia 
with a relatively well sourced health system, it is feasible 
to admit all patients with malaria for treatment and this 
ensures close supervision and maximal treatment effi-
cacy. In countries with greater case numbers, less well 
funded health systems or impoverished populations that 
rely on a daily income admitting all malaria patients to 
hospital is not feasible. DOTs programmes delivered 
by village workers might be an option in some settings 
as was recently discussed at a meeting in Cambodia 
[45], however this approach is not formally endorsed by 
WHO. Some participants suggested that incentives for 
village health workers would encourage them to remind 
patients to adhere to their treatment.
Adequate patient communication and simple messag-
ing have been shown to overcome poor adherence in set-
tings with low education and literacy rates [46]. Where 
P. vivax and P. falciparum are co-endemic some partici-
pants thought that it was important that patients were 
aware of the biomedical difference between the two spe-
cies. Explaining the long-term risk of P. vivax repeated 
infections due to its propensity to recur and the ben-
eficial effects of radical cure was considered essential in 
encouraging patients and their carers to complete a full 
course of treatment.
Alternative solutions were discussed including modern 
communication technologies such as messaging through 
mobile phones (SMS) or using specifically developed 
apps. Results from trials using SMS to increase adher-
ence to malaria treatment and to treatment for other 
diseases such as HIV and TB have shown mixed results 
[47–50]. Content and type of messaging need to be well 
developed, tested and refined and locally adapted for 
their implementation to be successful [51, 52]. Mobile 
applications have been developed to improve adherence 
to a range of other diseases however there is little knowl-
edge on whether they actually impact on adherence [53].
Topic 5: anticipated challenges for rolling 
out Tafenoquine
TQ is currently at the end of its phase 3 development pro-
gramme. Phase 3 read out anticipated in 2017 and subse-
quent licensing expected to follow in endemic countries 
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as approvals are gained. If marketed, TQ as a single dose 
radical cure will be a major advance in improving the 
adherence issues associated with PQ regimens. However, 
TQs long elimination half-life means that if drug induced 
signs of haemolysis occur treatment can’t be curtailed 
by ceasing further drug administration as is currently 
the case with PQ. This is likely to be particularly impor-
tant for patients with the Mediterranean variant in whom 
haemolysis continues without compensatory effect, but 
less important for those with mild or moderate variants.
Patients with G6PDd, particularly those with Mediter-
ranean variants, may be at risk of an extended period of 
haemolysis and for this reason prior testing for G6PDd 
is likely to be mandatory. Until more information has 
been gathered from heterozygous females with interme-
diate G6PDd (enzyme activity between 30 and 70%) the 
licence holder will restrict its use to those with a mini-
mum G6PD enzyme activity of 70%. Identification of 
patients at risk through a reliable quantitative PoC test 
will therefore be one of the greatest challenges for access 
to TQ [54]. Alternative solutions need to be considered 
in case no appropriate PoC test is available in time. Par-
ticipants suggested that patients could be referred to 
centres where quantitative testing, for instance using 
spectrophotometry, could be assured. It seems likely that 
the licence holder will insist on such safety precautions to 
ensure an acceptable risk–benefit ratio. However restrict-
ing the availability of TQ to tertiary centres with quan-
titative G6PD measurement facilities will significantly 
limit the number of patients receiving TQ treatment, and 
thus the public benefits.
Other challenges that need to be addressed prior to the 
introduction of TQ were also discussed. Current test-
ing and treatment of malaria is generally undertaken by 
healthcare and laboratory workers with limited training. 
Given the risk of sustained haemolysis following TQ, 
medical and laboratory personnel will require enhanced 
training on testing, interpretation of the results and treat-
ment protocols, as well as ensuring appropriate quality 
control processes are in place. Alternatively, higher levels 
of care may need to be provided, including more physi-
cian involvement, however this is unlikely to be feasible 
for many NMCPs.
Once appropriate PoC G6PD tests are available, these 
will need to be introduced at all outlets where adminis-
tration of TQ is envisaged. One option to facilitate this 
is to assess every vivax patient routinely prior to TQ 
treatment. Another option is to test patients only once, 
assuming no major changes in enzyme activity occur over 
a life-time, and to record the patient’s results on a register 
or patient card, which could be used to base decisions on 
treatment in the future. Whether records should be kept 
as hard or soft copy and whether results should remain 
with the patient or in a centralized repository will depend 
largely on the capacity of the NMCPs and the health care 
system in general. In Malaysia and the Philippines new-
borns have their G6PD activity measured. The carers of 
the babies are provided with cards indicating the results. 
Those tested normal will need to be tested again later in 
life to confirm their status, as G6PD levels are physiologi-
cally elevated in new-borns [55, 56]. The potential loss 
of cards over time, may limit the usefulness of the sys-
tem for many NMCPs [10]. In the absence of electronic 
patient record systems  and ongoing uncertainty regard-
ing the stability of enzyme activity over time in heterozy-
gous females, it is likely that most control programs will 
opt for repeated testing.
Adherence to test results and clear decision trees for 
adequate treatment of G6PDd patients will need to be 
developed and staff will require training and regular 
assessment on how well they are adhering to these pro-
tocols. Training of staff will need to include quality assur-
ance issues, appropriate handling of samples for testing, 
as well as adequate communication to patients about the 
prescription of TQ, its benefits and risks and alternate 
treatment options when TQ is contraindicated.
Conclusion
There are significant challenges for achieving safe and 
effective radical cure in the communities at greatest risk 
of malaria. NMCPs, researchers and funders need to 
address these challenges and create a viable strategy to 
achieve their goals, providing novel solutions for over-
coming critical bottle-necks. This process needs to begin 
now to enhance treatment practice for PQ based radi-
cal cure. Highlighting the benefits of radical cure for the 
patient and community will improve prescription prac-
tice and patient adherence. Coupling this with improved 
access to adequate G6PD testing will pave the way for the 
introduction of TQ, with huge potential to accelerate the 
elimination of P. vivax.
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